Skip to main content

DRDO developing DURGA II laser weapon for land, naval, air use?डीआरडीओ भूमि, नौसेना, वायु उपयोग के लिए दुर्गा II लेजर हथियार विकसित कर रहा है?

 DURGA-2

The classified project, dubbed

DURGA II (Directionally Unrestricted

Ray-Gun Array), will see the Indian

Army receive the 100-kilowat,

lightweight directed-energy system



IS IT THE SAME AS KALI 1

The KALI (Kilo Ampere Linear Injector)

It is a Directed-energy weapon designed to work in such a way that if an enemy missile is launched towards India, it will quickly emit powerful pulses of Relativistic electron beam and destroy the target. Unlike laser beams, it does not bore a hole in the target but thoroughly damages the on-board electronic systems.

  DURGA 2

The DRDO is currently requesting $100 million from the MoD for the 2021-2022 budget to produce a high-power laser weapon. DURGA IIl program is currently in the concept stage.
DURGA Il is to be integrated with land-, sea- and air-based platforms

DETAILS

DRDO laboratories engaged in the

development of directed-energy technology include the Laser Science and Technology Centre, the Defence Electronics Research Laboratory, the Defence Research and Development Laboratory, and the Centre for

High Energy Systems and Sciences.

In addition, the DRDO established
a firing range at its Terminal Ballistics Research Laboratory at Ramgarh in Haryana state, near New Delhi.


CHINA
China has also made efforts in developing directed-energy weapons, with state media and manufacturers releasing images and videos of hand- held and vehicle-mounted laser systems.
China's laser weapon capable of destroying Indian and US satellites, say analysts.

दुर्गा -2
 वर्गीकृत परियोजना, डब

 DURGA II (प्रत्यक्ष रूप से अप्रतिबंधित रे-गन एरे), भारतीय सेना को 100-किलोवाट, हल्के वजन की निर्देशित-ऊर्जा प्रणाली प्राप्त करते हुए देखेगे

 


 यह कली 1 के समान है

 काली (किलो एम्पियर रैखिक इंजेक्टर)

 यह एक डायरेक्टेड-एनर्जी हथियार है जिसे इस तरह से काम करने के लिए डिज़ाइन किया गया है कि अगर दुश्मन की मिसाइल को भारत की ओर लॉन्च किया जाता है, तो यह जल्दी से रिलेटिव इलेक्ट्रानिक बीम के शक्तिशाली दालों का उत्सर्जन करेगा और लक्ष्य को नष्ट कर देगा।  लेजर बीम के विपरीत, यह लक्ष्य में छेद नहीं करता है लेकिन ऑन-बोर्ड इलेक्ट्रॉनिक सिस्टम को पूरी तरह से नुकसान पहुंचाता है।

 दुर्गा २

 डीआरडीओ वर्तमान में 2021-2022 के बजट के लिए MoD से $ 100 मिलियन का अनुरोध कर रहा है ताकि एक उच्च-शक्ति लेजर हथियार का उत्पादन किया जा सके।  DURGA IIl कार्यक्रम वर्तमान में अवधारणा चरण में है।
 DURGA Il को भूमि-, समुद्र और वायु-आधारित प्लेटफार्मों के साथ एकीकृत किया जाना है

 विवरण

 डीआरडीओ प्रयोगशालाएं निर्देशित-ऊर्जा प्रौद्योगिकी के विकास में लगी हैं, जिनमें लेजर विज्ञान और प्रौद्योगिकी केंद्र, रक्षा इलेक्ट्रॉनिक्स अनुसंधान प्रयोगशाला, रक्षा अनुसंधान और विकास प्रयोगशाला और केंद्र शामिल हैं।

 उच्च ऊर्जा प्रणाली और विज्ञान।

 इसके अलावा, डीआरडीओ ने नई दिल्ली के पास, हरियाणा राज्य के रामगढ़ में अपने टर्मिनल बैलिस्टिक अनुसंधान प्रयोगशाला में फायरिंग रेंज स्थापित की।

 



 चीन

 चीन ने राज्य-मीडिया और निर्माताओं द्वारा हाथ से पकड़े गए और वाहन-चालित लेजर प्रणालियों के चित्र और वीडियो जारी करने के साथ, निर्देशित-ऊर्जा हथियार विकसित करने में भी प्रयास किए हैं।

 विश्लेषकों का कहना है कि भारतीय और अमेरिकी उपग्रहों को नष्ट करने में सक्षम चीन का लेजर हथियार।

Comments

Post a Comment

Popular posts from this blog

Mystery brain disease found in Canada

  WHAT HAS HAPPENED? An unknown brain disease has caused panic in the New Brunswick province of Canada after a string of cases were reported that involved memory loss, hallucinations and muscle atrophy. People living in the province became cognizant of the disease after a memo from the province's public health agency leaked last week, Which asked doctors to look for symptoms relate to Creutzfeldt-Jacob disease (CJD). CJD is a rare brain disease which is caused due to abnormally folded proteins called prions. Creutzfeldt-Jakob (KROITS-felt YAH-kobe) disease (CJD) is a degenerative brain disorder that leads to dementia and, ultimately, death. Creutzfeldt-Jakob disease symptoms can be similar to those of other dementia-like brain disorders, such as Alzheimer's disease. But Creutzfeldt-Jakob disease usually progresses much more rapidly. Transmitted by contact with infected tissue, such as during a transplant or from eating contaminated meat. CAUSES NOT KNOWN FOR CURRENT DISE...
Post a Comment
Read more

ANDHRA PRADESH STRAIN 15 TIMES MORE VIRULENT

  Experts are saying that a new Andhra Pradesh variant of the SARS-COV-2 virus is at least 15 times more virulent than the earlier ones. May be even stronger than the Indian variants of B. 1.617 and B. 1.618 . Speculation is still on regarding whether it is a new strain or the old N440K. The N440K variant was first discovered by Centre for Cellular and Molecular Biology (CCMB).However, data is still insufficient to confirm anythin. The impact of AP Strain Authorities say that the variant at present which is in circulation in Visakhapatnam is different from what we have seen during the first wave last year. Samples have been sent to CCMB for analysis, in order to find out which strain is in circulation right now.It has been observed that the new variant has shorter incubation period and the progress of the disease is much rapid. In the earlier cases, a patient infected with the virus would take at least a week to reach the hypoxia or dyspnea stage. But in the present context,...
Post a Comment
Read more

Anti-Covid drug developed by DRDO

  WHAT HAS HAPPENED? The Drugs Controller General of India (DCG) has approved the emergency use of Drug 2-deoxy-D-glucose (2-DG) as an adjunet therapy in moderate to severe Covid-19 patients. WHO DEVELOPED IT? The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRD0), has developed the drug, In collaboration with Dr Reddy's Laboratories, Hyderabad. WHEN & HOW IT WAS DEVELOPED? In April 2020 , during the first wave of the pandemic, INMAS-DRDO scientists conducted laboratory experiments with the help of Centre for Cellular and Molecular Biology (CCMB), Hyderabad and Found that this molecule works effectively against SARS-CoV-2 virus and inhibits the viral growth. Based on these results, Drugs Controller General of India's (DCG) Central Drugs Standard Control Organization (CDSCO) permitted Phase-II clinical trial of 2-DG in COVID-19 patients in May 2020 . The DRDO, along with its industry partner DRL, Hyd...
Post a Comment
Read more